| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1995;60:1583-1591
© 1995 The Society of Thoracic Surgeons
Division of Cardiovascular and Thoracic Surgery, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, and Eppley Institute for Cancer Research and Department of Pathology, University of Nebraska Medical Center, Omaha, Nebraska
Background. Mutation or deregulation of certain cellular genes (protooncogenes) results in expression of proteins that appear to promote malignant transformation. Human non-small cell lung cancer has been documented to express many such oncogenes including c-myc, bcl-2, and mutant p53. Antisense oligodeoxyribonucleotides (ASODN) complementary to these oncogenes were tested on three non-small cell lung cancer cell lines for their efficacy in inhibiting cellular proliferation and oncoprotein expression.
Methods. Established non-small cell lung cancer cell lines A427, SKMES-1, and A549 were grown in the presence of ASODNs complementary to messenger RNA of c-myc, bcl-2, p53, or controls at 1 µmol/L or 10 µmol/L concentrations for 4 or 10 days. Cellular proliferation was measured by tritiated thymidine uptake. Flow cytometry was used to quantitate oncoprotein expression. Intranuclear ASODN uptake was documented by fluoresceine-tagged ASODNs.
Results. Fluoresceine-tagged ASODNs were readily taken up by all cell lines. c-myc, as well as bcl-2 and p53 ASODNs, were found to inhibit proliferation of all cell lines significantly compared with controls, most notably in line A549 (40.1% ± 7.1% of control, p = 0.000 with c-myc ASODN). Antisense c-myc reduced c-myc protein by as much as 71.3% in A427, although protein levels were only minimally reduced in the viable cells of the other lines.
Conclusions. c-myc ASODNs inhibit proliferation of non-small cell lung cancer cell lines as well as reduce c-myc protein expression. Antisense bcl-2 and p53 also cause similar growth inhibition. These results suggest a critical role for activation of these oncogenes in the growth of cultured lung cancer cells. Furthermore, the efficacy and rapid cellular uptake of ASODNs support the potential role of antisense targeting of oncogene expression for pharmacologic control of non-small cell lung cancer.
Related Article
Ann. Thorac. Surg. 1995 60: 1591.
This article has been cited by other articles:
|
|
 |
|
  B. H. Yoo, E. Bochkareva, A. Bochkarev, T.-C. Mou, and D. M. Gray 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro Nucleic Acids Res., April 2, 2004; 32(6): 2008 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Moon, Y. Oh, and J. A. Roth Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5055 - 5067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Junghans, J. Kreuter, and A. Zimmer Antisense delivery using protamine-oligonucleotide particles Nucleic Acids Res., May 15, 2000; 28(10): e45 - e45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Bunn Jr., A. Soriano, G. Johnson, and L. Heasley New Therapeutic Strategies for Lung Cancer : Biology and Molecular Biology Come of Age Chest, April 1, 2000; 117(4_suppl_1): 163S - 168S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, B. Lin, A. Agadir, R. Liu, M. I. Dawson, J. C. Reed, J. A. Fontana, F. Bost, P. D. Hobbs, Y. Zheng, et al. Molecular Determinants of AHPN (CD437)-Induced Growth Arrest and Apoptosis in Human Lung Cancer Cell Lines Mol. Cell. Biol., August 1, 1998; 18(8): 4719 - 4731. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
